Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
about
New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid ParasitesPentavalent antimonials: new perspectives for old drugsDual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovaniSodium stibogluconate (Pentostam) potentiates oxidant production in murine visceral leishmaniasis and in human bloodDrug resistance in leishmaniasisResistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production.Systemic therapy of New World cutaneous leishmaniasis: A case report and review article.Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials.Structures, targets and recent approaches in anti-leishmanial drug discovery and development.Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway.Current therapies for treatment of cutaneous leishmaniasis in India.Use of antimony in the treatment of leishmaniasis: current status and future directions.Current treatment recommendations for leishmaniasis.A lupane-triterpene isolated from Combretum leprosum Mart. fruit extracts that interferes with the intracellular development of Leishmania (L.) amazonensis in vitro.Antileishmanial drug targeting through glycosylated polymers specifically internalized by macrophage membrane lectins.Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.Drug delivery strategies for therapy of visceral leishmaniasis.Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal.Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes.Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexesAxenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.Phosphoproteomic analysis of wild-type and antimony-resistant Leishmania braziliensis lines by 2D-DIGE technology.Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis.Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.
P2860
Q28068159-2D0B06C8-F440-4E4C-B6EC-37F3F2344B78Q28253055-FF8D382A-C4FE-4A9A-9C1B-2A2ADB5EB0F3Q28271918-DE6EDC1B-E384-4407-B05D-96A33788FE2BQ28344600-87AE4716-709D-48C6-AC0B-ABCECFA67DE6Q29616242-D5C25745-82BA-46CC-B141-D7D97C3B1AB2Q33633393-BE369083-C5E8-40AA-B7BE-88A708A6D1C8Q34028355-16666ED7-D409-4950-B8C1-1E9AB82C82A2Q34058179-DDEABF55-3D7C-488F-AEE0-F188CDC936EFQ35012968-30D32F1D-757E-4072-AFDD-FCD155CAE17BQ35122124-1A9C6FA7-FFCA-4ACD-B409-F2F2F88CB701Q35232935-C4197668-F601-4D7C-B062-2DD986B71256Q35377767-11985B6D-671A-48B1-A0B4-B1C6BCE8D044Q35653378-9C24C83E-5C1B-4BAF-908C-66EF20E0234BQ35655177-A71C26C5-A6BE-4735-9E35-5978F94CC933Q36757841-12A59D38-FA11-43E3-8097-4D06E562AB11Q37515690-3094196E-F349-49AC-847C-ED8E24071B06Q37702257-278907EA-9F3D-4A2F-8D6C-BAB04C857044Q38968281-652A582A-AC80-4364-AABC-3EABB2A446D0Q39469739-230E0674-1698-4671-B0A7-95E0643CDE12Q39477783-581A5338-C752-407C-BC38-5CB70175631FQ39558272-F5A56A94-5561-43BF-A4C0-58779D0EB7E1Q39559595-E36C4C64-5214-4D9A-A3F9-78321FCC7A0BQ39784088-E142B915-BF74-433A-913D-EAF4E4625781Q40800476-97077635-90A7-408D-8440-3270064BC709Q40955917-DBFC9A74-857A-4577-987A-FD317D8CB5BBQ43505317-46C457C6-561B-4411-894F-9167E793F755Q54027189-9F6285EB-4300-453F-B335-8EA35CEC355E
P2860
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
@en
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
@nl
type
label
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
@en
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
@nl
prefLabel
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
@en
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
@nl
P2093
P2860
P356
P1476
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
@en
P2093
P2860
P304
P356
10.1128/AAC.27.6.916
P407
P577
1985-06-01T00:00:00Z